Molecular prostate cancer pathology: Current issues and achievements

References

• Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144–8.
   PubMed Web of Science ®Google Scholar
• Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358–68.
   PubMed Web of Science ®Google Scholar
• Montironi R, Mazzucchelli R, Scarpelli M. Molecular techniques and prostate cancer diagnostic. Eur Urol 2003; 44:390–400.
   Google Scholar
• Petricoin EF, Liotta LA. Proteomic analysis at the bedside: early detection of cancer. Trends Biotechnol 2002;20:S30–4.
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha C, Rhodes DR, Yu J, et al. Prostate cancer biomarkers: a current perspective. Expert Rev Mol Diagn 2003;3:459–70.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK, et al. Environ-mental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78–85.
   PubMed Web of Science ®Google Scholar
• Monroe KR, Yu MC, Kolonel LN, et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995;1:827–9.
   PubMed Web of Science ®Google Scholar
• Simard J, Dumont M, Labuda D, et al. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 2003;10:225–59.
   PubMed Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomar-kers Prey 2003;12:1429–37.
   PubMed Web of Science ®Google Scholar
• Bookstein R, MacGrogan D, Hilsenbeck SG, et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369–73.
   PubMed Web of Science ®Google Scholar
• Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85: 1657–69.
   PubMed Web of Science ®Google Scholar
• Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017–9.
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Nomoto S, Caballero OL, et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001;20:5195–8.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway? Biol Chem 2002;383:1045–57.
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Yousef GM. Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev Mol Diagn 2001;1:182–90.
   PubMedGoogle Scholar
• Li S, Hursting SD, Davis BJ, etal. Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann N Y Acad Sci 2003; 983:161–9.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415–28.
   PubMed Web of Science ®Google Scholar
• Goessl C, Krause H, Muller M, et al. Fluorescent methyla-tion-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941–5.
   PubMed Web of Science ®Google Scholar
• Liu L, Yoon JH, Dammann R, et al. Frequent hypermethy-lation of the RASSF1A gene in prostate cancer. Oncogene 2002;21:6835–40.
   PubMed Web of Science ®Google Scholar
• Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002;62:3498–502.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Bennett CJ, Hicks JL, etal. Hypermethylation of the human glutathione 5-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflamma-tory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003;163:923–33.
   PubMed Web of Science ®Google Scholar
• Lee WH, Morton RA, Epstein JI, etal. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogen-esis. Proc Natl Acad Sci U S A 1994;91:11733–7.
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 2001;945:51–8.
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001;58:335–8.
   PubMed Web of Science ®Google Scholar
• Gonzalgo ML, Pavlovich CP, Lee SM, et al. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003;9:2673–7.
   PubMed Web of Science ®Google Scholar
• Lin B, Ferguson C, White IF, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999;59:4180–4.
   PubMed Web of Science ®Google Scholar
• Schmitz W, Albers C, Fingerhut R, et al. Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 1995;231:815–22.
   PubMedGoogle Scholar
• Michaud DS, Augustsson K, Rimm EB, et al. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001;12:557–67.
   PubMed Web of Science ®Google Scholar
• Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220–6.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JANIA 2002;287:1662–70.
   PubMed Web of Science ®Google Scholar
• Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Tirol 2001;166: 2171–7.
   Google Scholar
• Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683–8.
   PubMed Web of Science ®Google Scholar
• Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001; 61:5692–6.
   PubMed Web of Science ®Google Scholar
• Stephan C, Yousef GM, Scorilas A, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004;171:187–91.
   PubMed Web of Science ®Google Scholar
• Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer 2002;2:627–33.
   PubMed Web of Science ®Google Scholar
• Meid FH, Gygi CM, Leisinger HJ, et al. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol 2001;165:1802–5.
   PubMed Web of Science ®Google Scholar
• De Kok JB, Verhaegh GW, Roelofs RW, etal. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695–8.
   PubMed Web of Science ®Google Scholar
• Burger MJ, Tebay MA, Keith PA, et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 2002;100:228–37.
   PubMed Web of Science ®Google Scholar
• Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expres-sion with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357–62.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Adam BL, Cazares LH, etal. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029–33.
   PubMed Web of Science ®Google Scholar
• Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975–9.
   PubMed Web of Science ®Google Scholar
• Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diag-nosis of prostate cancer. Eur Urol 2003;44:8–15.
   PubMed Web of Science ®Google Scholar
• Oliveira JDD, Goulart LR, Waldesse PO, et al. DD3 gene expression in peripheral blood of patients with prostate cancer and with benign hyperplasia as a molecular diagnos-tic. The 5th World Congress on Urological Research, London, 2003. p. 102.
   Google Scholar
• Cornford P, Evans J, Dodson A, et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999;154:137–44.
   PubMed Web of Science ®Google Scholar
• Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099–105.
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624–9.
   PubMed Web of Science ®Google Scholar
• Foster CS, Falconer A, Dodson AR, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004;23:5871–9.
   PubMed Web of Science ®Google Scholar
• De la TA, Olsson CA, Katz AE. Molecular staging of prostate cancer: dream or reality? Oncology (Huntingt) 1999;13:187–94.
   PubMedGoogle Scholar
• Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implica-tions for detection of micrometastases. Cancer Res 1995;55: 2640–4.
   Google Scholar
• Henke W, Jung M, Jung K, et al. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. hit J Cancer 1997;70:52–6.
   PubMed Web of Science ®Google Scholar
• Ylikoski A, Pettersson K, Nurmi J, et al. Simultaneous quantification of prostate-specific antigen and human gland- ular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease. Clin Chem 2002;48: 1265–71.
   PubMed Web of Science ®Google Scholar
• Moreno JG, O'Hara SM, Long JP, et al. Transrectal ultrasound-guided biopsy causes hematogenous dissemina-tion of prostate cells as determined by RT-PCR. Urology 1997;49:515–20.
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Wang ZP, Shue M, et al. Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells. J Urol 1999;162:749–52.
   PubMed Web of Science ®Google Scholar
• Hlavaty JJ, Partin AW, Shue MJ, et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003;61:1261–5.
   Google Scholar
• Nakamura T, Scorilas A, Stephan C, et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003;63:6543–6.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski MK, Recker F, Piironen T, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998;52:360–5.
   PubMed Web of Science ®Google Scholar
• Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170:723–6.
   PubMed Web of Science ®Google Scholar